Prevalence & determinants of depression in type 2 diabetes patients in a tertiary care centre.
Abstract: Background & objectives: Depression is common among people with diabetes and it is associated with poor outcomes. This study was carried out to investigate the prevalence and determinants of depression in patients with established type 2 diabetes (T2DM) attending a tertiary care hospital in north India.

Methods: Patients with established T2DM were evaluated for depression by administering the nine-item PHQ-9 (Hindi version). Binary logistic regression model was used to examine association between predictor variables and risk of depression. Results were expressed as odds ratio and 95 per cent confidence interval. Cronbach alpha was calculated to assess internal consistency of PHQ-9.

Results: Patients with T2DM (n=300) were evaluated [147(49%) male and 153(51%) female]. The median duration of diabetes (IQ) was 8(4-13) yrs. Of the study patients, 68 (23%) met the criteria for major depression, 54 (18%) for moderate depression and the remaining 178 (59%) had no clinically significant depression. Depression was strongly associated with age >54 yr (OR 1.26, 95% CI 1.02-1.67; P<0.05), central obesity (OR 1.34, 95% CI 1.04-1.64; P<0.001), neuropathy (OR 1.94, 95% CI 1.03-3.66; P=0.002), nephropathy (OR 1.81, 95% CI 1.02-3.21; P=0.041), peripheral vascular disease (OR 6.08, 95% CI 1.0734.6; P=0.042), diabetic foot disease (OR 2.32, 95% CI 1.06-5.86; P<0.001) and pill burden (>4) (OR 1.27, 95%CI 1.01-1.44; P=0.035). However, the likelihood of depression was not significant with duration of diabetes and insulin use.

Interpretation & conclusion: This study showed high prevalence of depression in patients with T2DM. The risk factors for depression were age, central obesity, diabetic complications particularly neuropathy and diabetic foot disease and increased pill burden.

Key words Depression--diabetic complications--pill burden--T2DM
Article Type: Report
Subject: Major depressive disorder (Risk factors)
Type 2 diabetes (Psychological aspects)
Diabetics (Psychological aspects)
Authors: Raval, Amit
Dhanaraj, Ethiraj
Bhansali, Anil
Grover, Sandeep
Tiwari, Pramil
Pub Date: 08/01/2010
Publication: Name: Indian Journal of Medical Research Publisher: Indian Council of Medical Research Audience: Academic Format: Magazine/Journal Subject: Biological sciences; Health Copyright: COPYRIGHT 2010 Indian Council of Medical Research ISSN: 0971-5916
Issue: Date: August, 2010 Source Volume: 132 Source Issue: 2
Geographic: Geographic Scope: India Geographic Code: 9INDI India
Accession Number: 237135677
Full Text: Diabetes is a chronic disease which affects virtually every organ in the human system. The World Health Organization projected that 300 million people will suffer from diabetes by 20251. India has the largest number of diabetic population in the world and it is expected that there will be 69.9 million diabetic populations in India by 2025 (1).

Depression is common among people with diabetes (2), and it is associated with worse diabetes outcomes (3,4). The prevalence of depression is higher in patients with diabetes who have long-term complications (4,5). Compared with patients with diabetes alone, patients with depression and diabetes have been shown to have poorer self-management and poor adherence to antidiabetic, lipid-lowering and antihypertensive treatment (6). They are more likely to have higher cardiovascular risk factors like smoking, obesity, sedentary lifestyle, and uncontrolled hyperglycaemia (5). Depression may be an important barrier to effective diabetes management. Patients with depression and diabetes are more likely to have higher macrovascular and microvascular complications (4) and higher mortality rates (7).

While depression may contribute to poor diabetes-related outcomes, diabetes and its complications may also contribute to poor depression outcomes (6,8,9). The available data regarding the prevalence of depression in type 2 diabetes (T2DM) patients in India are limited. We investigated the prevalence and determinants of depression in patients with T2DM attending a tertiary care hospital in north India, and its relationship with glycaemic control, diabetic complications, demographic and socio-economic factors was examined.

Material & Methods

This cross-sectional study was carried out from June 2008 to March 2009 at the Nehru Hospital, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. All consecutive patients with T2DM attending the Endocrinology Outpatient Clinic in Nehru Hospital, were evaluated. Informed and written consent was obtained from all the participants. The study protocol was approved by the Institute's Ethics Committee. Patients with established T2DM as defined by American Diabetes Association (ADA 1997) criteria (10) were examined consecutively for depression by PHQ-9 (a subset of the Patients Health Questionnaire) (11). Further, Social, demographical and clinical variables were also assessed.

Depression was assessed by administering the nine-item PHQ-9, a self report version of PRIME-MD (11) which assesses the presence of major depressive disorder using modified Diagnostic and Statistical Manual, Fourth edition (DSM-IV) criteria. There is good agreement reported between the PHQ diagnosis and those of independent psychiatry health professionals (for the diagnosis of any one or more PHQ disorder, kappa=0.65; overall accuracy, 85%; sensitivity, 75%; specificity, 90%) (12,13). In this study Hindi version of PHQ-9 was used. It has been validated in Indian population and is considered to be reliable tool for diagnosis of depression (14). The PHQ-9 is a dual instrument that is used to establish a provisional depressive disorder as well as it provides a symptoms severity score. For the diagnosis of depression, we defined clinical significant depression as: a PHQ-9 score of 8-9 as minor depression, a PHQ-9 score of 10 or greater as moderate depression; a score of 15 or more and one of the two cardinal symptoms (either depressed mood or anhedonia) as definite major depression12,13. Patients who did not understand the questionnaires or deaf or not able to answer (i.e., unconscious) or on wheel chair were excluded.

Anthropometric measurements: Standing body height (to the nearest 0.1 cm) was measured with a commercial stadiometer. A digital scale, with an accuracy of [+ or -] 100 g, was used to measure body weight (BW). The waist circumference (WC) was measured in a horizontal plane, midway between the inferior margin of the ribs and the superior border of the iliac crest. The measurements were taken thrice and the mean was taken as the final reading. Body mass index (BMI) (kg/ [m.sup.2]) was calculated by dividing weight (in kilograms) by the square of height (in meters), as a measure of total adiposity.

Systolic and diastolic blood pressure (SBP & DBP) was measured twice at an interval of 3 min in the sitting position after a 15 min rest, and the mean was taken. Blood samples (3 ml) were drawn after 8-12 h overnight fasting for the measurement of lipid profile [total cholesterol (TC), high density lipoprotein (HDL) cholesterol, and triglycerides (TG)] and fasting plasma glucose (FPG) levels. Plasma glucose was measured using the glucose oxidase method (15), serum total cholesterol (16) and triglycerides (17) by standard enzymatic procedures and HDL cholesterol (18) by direct assay method.

Neuropathy was evaluated by history and of clinical examination using 10 g monofilament, vibration sense by biothesiometer (VPT at great toe >25 mV were considered significant) and ankle reflex (19). Incipient nephropathy was diagnosed by Micral test (20) and it was presumed to be present if any two readings out of three of urinary albumin to creatinine ratio were ranging from 30 to 300 ([micro]g/mg. Clinical nephropathy was evaluated by the estimation of 24 h urine protein and it was present if urine proteins were more than 500 mg/total volume of urine (21). Ophthalmologist diagnosed retinopathy by detailed fundus examination and was classified according to Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS) (22). Coronary artery disease (CAD) was diagnosed by history of angina or myocardial infarction or documented by previous treatment records. Interpretation of ECG was recorded as per Minnesota codes. Peripheral vascular disease (PVD) was diagnosed by definitive history of intermittent claudication or if two or more peripheral pulses were absent in both feet. The grading was done according to ankle brachial index (ABI) by Doppler Study [Multi Duplex(R)-II (Huntleigh Diagnostics--UK)]. PVD was diagnosed when ankle brachial index was less than 0.9.

Statistical analysis: Data were reported as the mean [+ or -] SD or percentages, for skewed data median (Interquartile range) was reported. Differences in characteristics between participants were tested with unpaired t test for normally distributed variables, with the Wilcoxon rank sum test for skewed variables, and with the chi-square test or fisher exact test for categorical variables. The significance level was set at 5 per cent. Binary logistic regression model was used to examine association between predictor variables (as captured by data capturing form) and risk of depression. The main model consists of following predictor variables: demographic variables age, gender, obesity, clinical variables like diabetic complications, blood pressure and duration of disease, etc. Results were expressed as odds ratio (OR) and 95 per cent confidence intervals (CI). Cronbach alpha was calculated to assess internal consistency of PHQ-9. All statistical analyses were carried out using Statistical Package for Social Sciences (SSPS) (Version 17.0, USA).

Results & Discussion

A total of 300 T2DM patients including 147 (49%) men and 153 (51%) women were evaluated. The mean age [+ or -] SD of patients was 54.2 [+ or -] 10 yr. The median (interquertile range) duration of diabetes was 8 (4-13) yr. Among the patients, 205 (68%) were hypertensive and the median duration of hypertension was 3 (0.7-8) yr . Microvascular (85% men vs. 69% women, P<0.001) and macrovascular complications (27% men vs. 13% women, P<0.001), both were higher in men (Table I). Of the patients assessed, 68 (23%) patients fulfilled the criteria for severe depression, 54 (18%) for moderate depression and 178 (59%) patients had no clinically significant depression. Internal consistency of PHQ-9 was evaluated using Cronbach alpha. Cronbach alpha was 0.84 indicating good consistency of this psychometric scale (PHQ-9) in the study population.

This study showed that more than one third of patients with T2DM were ailing from moderate to severe depression. The prevalence of depression in T2DM patients in our study was 41 per cent. The data regarding the prevalence of depression in patients with T2DM from India are scarce. However, studies from USA and UK reported the prevalence of depression in patients with T2DM varying from 30 to 83 per cent (23,24). A small study from Iran reported 55 per cent prevalence of depression in patients with T2DM (25). Similarly, a meta analysis by Anderson et al (26) identified the prevalence of depression in diabetes ranging from 8 to 61 per cent.

The likelihood of depression was significantly higher with age [greater than or equal to] 54 yr (OR 1.26, 95% CI 1.02, 1.67; P<0.05). Depression was most strongly associated with monthly income >5000 INR (OR 1.22, 95% CI 1.03-1.41; P<0.001), greater waist circumference

(OR 1.34, 95% CI 1.04-1.64; P<0.001), neuropathy

(OR 1.94, 95% CI 1.03-3.66; P=0.002), nephropathy (OR 1.81, 95% CI 1.02-3.21; P=0.041), peripheral vascular disease (OR 6.08, 95% CI 1.07-34.6; P=0.042), diabetic foot (OR 2.32, 95% CI 1.06-5.86; P<0.001) and pill burden >4 (OR 1.27, 95% CI 1.011.44; P=0.035). However, the likelihood of depression was not significant with gender, duration of diabetes, duration of hypertension, rural vs. urban residence, education, hyperglycaemia, hypertension, insulin use, retinopathy as well as cerebrovascular disease (Table II).

Advancing age is usually associated with depression as has been shown in earlier studies (5,24) and more so in patients with T2DM, as was also observed in our study. The data regarding the predilection of gender with depression are conflicting (27-29). Studies from the West have suggested the higher prevalence of depression in women as compared to men (30,31). The higher prevalence of depression in women is influenced by adverse experiences, sociocultural roles, psychological attributes, biological factors including hormones and poor social support as these are the major determinants for higher prevalence of depression in women. One of the reasons of lack of gender predilection in our study may be due to lesser diabetes related complications in women as compared to men and relatively better social fabric and support. Another important variable which showed strong association with T2DM was central obesity. There is a strong and robust association between obesity and depression as many studies have reported earlier (5,32,33). Altered body image associated with obesity and co-morbidities further perpetuate the depression. The increasing incidence of T2DM in part, is due to increase in prevalence of obesity therefore obesity, depression and diabetes make it vicious in genesis of disease and poses a challenge in management as well.

There are conflicting reports regarding the association between glycaemic control and depression (3,5,26). Poor glycaemic control may result in depression and vice versa depression may result in poor glycaemic control. However, in our study there was no difference in Hb[A.sub.1c] level in patients with and without depression. As expected the number of prescribed medicines had a bearing on patients' behaviour and in our study a strong association between depression and pill burden was seen similar to literature (5).

The DM complications strongly influence the outcome and both micro- and macrovascular complications were observed associated with higher prevalence of depression particularly neuropathy, nephropathy and diabetic foot disease. Similar to our findings weak association with retinopathy was reported by Nailboff and Rosenthal (34). Association of diabetic foot disease showed a strong association with depression irrespective of aetiology, whether it was neuropathic or neuroischemic foot disease. This happens because patients become invalid because of foot disease, treatment cost, prolonged hospital stay and subsequently poor rehabilitation make it worst among all the diabetic complications. The limitations of this study included its cross-sectional nature, hence, causal relationships between depression and variables could not be assumed, and small sample size.

In conclusion, our study showed high prevalence of depression in patients with T2DM. The risk factors for depression were age, central obesity, diabetic complications particularly neuropathy and diabetic foot disease and increased pill burden. The depression and diabetes are causally related and deserves attention from clinicians to ensure better management.

Conflict of interest: None.

Received May 20, 2009


(1.) King H, Auburt RE, Herman WH. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.

(2.) Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993; 16: 1167-78.

(3.) Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-42.

(4.) de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta analysis. Psychosomatic Med 2001; 63: 619-30.

(5.) Katon WJ, Simon G, Russo J, Von Korff M, Lin EH, Ludman E, et al. Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care 2004; 42: 1222-9.

(6.) Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004; 27: 2154-60.

(7.) Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28: 2668-72.

(8.) Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2001; 25: 464-70.

(9.) Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older mexican americans with type 2 diabetes. Diabetes Care 2003; 26: 2822-8.

(10.) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.

(11.) Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-44.

(12.) Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-13.

(13.) Wittkampf KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the Patient Health Questionnaire: a systematic review. Gen Hosp Psychiatry 2007; 29: 388-95.

(14.) Kochhar PH, Rajadhyaksha SS, Suvarna VR. Translation and validation of brief patients health questionnaire against DSM IV as a tool to diagnose major depressive disorder in Indian patients. J Postgrad Med 2007; 53: 102-7.

(15.) Trinder P. Determination of blood glucose using an oxidase peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969; 22: 158-61.

(16.) Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.

(17.) Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.

(18.) Lang PD, Schettler G. Arteriosklerose. In: Schettler G, Gross R, editors. Grundlageon-Diagnostik-Therapie. Cologne/W. Germany: Deutscher Arzte Verlag GmbH; 1985.

(19.) Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-22.

(20.) Standards of Medical Care in Diabetes American Diabetes Association. Diabetes Care 2008; 31: s12-31.

(21.) Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1): S79-83.

(22.) Grading diabetic retinopathy from stereoscopic colour fundus photographs- an extension of modified Airlie House classification. ETDRS report No 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalamology 1991; 98 (Suppl 5): 786-806.

(23.) Li C, Ford ES, Strine TW, Mokdad AH. Prevalence of depression among U.S. adults with diabetes: findings from the 2006 behavioral risk factor surveillance system. Diabetes Care 2008; 31: 105-7.

(24.) Kendrick T, Dowrick C, McBride A, Howe A, Clarke P, Maisey S, et al. Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data. Br Med J 2009; 338: 750.

(25.) Khamseh ME, Baradaran HR, Rajabali H. Depression and diabetes in Iranian patients: a comparative study. Int J Psychiatry Med 2007; 37: 81-6.

(26.) Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of co morbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-78.

(27.) Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med 2009; 26: 153-61.

(28.) Engum A, Mykletun A, Midthjell K, Holen A, Dohl AA. Depression and diabetes: a large population-based study of sociodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes. Diabetes Care 2005; 28: 1904-9.

(29.) Piccinelli M, Wilkinson G. Gender differences in depression. Br J Psychiatry 2000; 177: 486-92.

(30.) Culbertson FM. Depression and gender. An international review. Am Psychol 1997; 52: 25-31.

(31.) Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23: 1165-73.

(32.) Gudelj-Radic J, Davidovic D, Avramovic D, Backovic D, Jorga J. Factors mediating the depression in the adult obese outpatients. Srp Arh Celok Lek 2007; 135: 61-6.

(33.) Sacco WP, Wells KJ, Friedman A, Matthew R, Perez S, Vaughan CA. Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy. Health Psychol 2007; 26: 693-700.

(34.) Naliboff BD, Rosenthal M. Effects of age on complications in adult onset diabetes. J Am Geriatr Soc 1989; 37: 838-42.

Reprint requests: Prof. Anil Bhansali, Head, Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India e-mail:

Amit Raval, Ethiraj Dhanaraj, Anil Bhansali *, Sandeep Grover ** & Pramil Tiwari

Department of Pharmacy Practice, National Institute of Pharmaceutical Education & Research (NIPER), SAS Nagar, Punjab & Departments of * Endocrinology & ** Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India
Table I. Demographic and clinical characteristics of patients with T2DM

                              Overall                Male
Characteristics              300 (100%)             147 (49%)

Age (yr)                 54.2 [+ or -] 10.0     55.1 [+ or -] 9.2
DOD (yr) (+)                 8 (4-13)              8 (4-15)
DHTN (yr) (+)                3 (0.7-8)             3 (0.5-8)
BMI (kg/[m.sup.2]) (+)    25.4 (22.3-29.0)      23.9 (21.7-27.1)
Waist (cm)                91.7 [+ or -] 12.3    91.3 [+ or -] 12.6
FPG (mg/dl) (+)            149 (115-198)         133 (110-177)
PPPG (mg/dl) (+)           206 (159-265)         200 (154-250)
HbA1c (%)                  9.0 [+ or -] 2.3      8.7 [+ or -] 2.1
TC (mg/dl)               180.6 [+ or -] 50.8   174.7 [+ or -] 49.2
HDL (mg/dl)               47.8 [+ or -] 20.2    47.7 [+ or -] 20.6
LDL (mg/dl)              101.4 [+ or -] 34.5    94.6 [+ or -] 33.5
TG (mg/dl) (+)              177 (148-210)        140 (103-194)
Complications n (%)
  Microvascular               231 (77)              125 (85)
  Complications any
  Neuropathy                  194 (65)              112 (76)
  Nephropathy                 106 (35)               56 (38)
  Retinopathy                 116 (39)               65 (44)
  Non Proliferative            47 (16)               16 (11)
  Proliferative                69 (23)               49 (33)
  Macrovascular                60 (20)               40 (27)

    Complications any
      CAD                      31 (10)               19 (13)
      PVD                      13 (4)                10 (7)
      Stroke                    7 (2)                 5 (3)
      Diabetic foot            21 (7)                18 (12)
      Amputation               10 (3)                10 (7)

Characteristics               153 (51%)

Age (yr)                   54.4 [+ or -] 11.5
DOD (yr) (+)                7.5 (4-12)
DHTN (yr) (+)                 3 (1-9)
BMI (kg/[m.sup.2]) (+)     26.5 (23.4-31.2) **
Waist (cm)                 92.2 [+ or -] 11.8
FPG (mg/dl) (+)             156 (118-208) *
PPPG (mg/dl) (+)            216 (168-268)
HbA1c (%)                   9.4 [+ or -] 2.5
TC (mg/dl)                187.4 [+ or -] 51.9
HDL (mg/dl)                47.9 [+ or -] 19.7
LDL (mg/dl)               109.0 [+ or -] 4.2 *
TG (mg/dl) (+)              170 (120-239) *
Complications n (%)
  Microvascular               106 (69) **
  Complications any
  Neuropathy                   82 (54) **
  Nephropathy                  50 (33) **
  Retinopathy                  51 (33) **
  Non Proliferative            31 (20) **
  Proliferative                20 (13) **
  Macrovascular                20 (13) **

    Complications any
      CAD                     12 (8) **
      PVD                      3 (2) *
      Stroke                   2 (1) *
      Diabetic foot            3 (2)
      Amputation               0 (0) **

P * <0.05, ** <0.001 compared to male. Values are mean [+ or -] SD.
(+) median (interquartile range)

DOD, duration of diabetes; DHTN, duration of hypertension; BMI, body
mass index; CAD, coronary artery disease; PVD, peripheral vascular

Table II. Binary logistic regression analyses showing risk factors
associated with depression in T2DM patients

                                          Odds ratio
Risk factors                              (95% CI)           P value

Age (<54 vs. >54 yr)                      1.26 (1.02-1.67)   <0.05
Gender (Male vs. Female)                  1.11 (0.63-1.95)    0.70
Duration of diabetes                      1.03 (0.79-1.34)    0.23
  ([less than or equal to] 9 vs. >9 yr)
Duration of hypertension                  0.87 (0.67-1.07)    0.56
  ([less than or equal to] 3 vs. >3 yr)
Area of residence                         0.76 (0.44-1.34)    0.35
(Rural vs. Urban)
Income ([less than or equal to] 5000      1.22 (1.03-1.41)   <0.001
  vs. >5000 INR/month)
Education (literate vs. illiterate)       1.12 (0.93-1.46)    0.07
BMI ([less than or equal to] 25 vs. >25   1.21 (0.98-1.35)    0.05
Waist *                                   1.34 (1.04-1.64)   <0.001
Hb[A.sub.1c] ([less than or equal to] 7   1.82 (0.92-3.12)    0.09
  vs. >7 %)
SBP ([less than or equal to] 130 vs. >    1.23 (0.89-1.45)    0.35
  130 mmHg)
DBP ([less than or equal to] 80 vs. >80   1.01 (0.99-1.03)    0.24
Neuropathy                                1.94 (1.03-3.66)    0.002
Nephropathy                               1.81 (1.02-3.21)    0.041
Retinopathy                               1.18 (0.78-1.79)    0.43
Microvascular complications               2.39 (1.14-5.04)    0.022
CAD                                       2.07 (0.95-4.51)    0.066
PVD                                       6.08 (1.07-34.6)    0.042
CVA                                       1.71 (0.28-10.5)    0.561
Diabetic foot                             2.32 (1.06-5.86)   <0.001
Macrovascular                             2.27 (1.20-4.30)    0.012
complications any
Dyslipidaemia **                          0.57 (0.18-1.85)    0.355
Insulin use                               1.08 (0.60-1.95)    0.796
Number of prescribed                      1.27 (1.01-1.44)    0.035
medicine ([less than or equal to] 4
  vs. >4)

* Waist (for male [less than or equal to] 80 vs. >80 cm and female
[less than or equal to] 90 vs. >90 cm, sex adjusted odds ratio was
calculated); ** Dyslipidaemia is defined as TC and TG >150 mg/dl
or LDL >100 mg/dl or HDL <40 mg/dl for male and <50mg/dl for female.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; CAD, coronary artery disease; PVD, peripheral
vascular disease; CVA, cerebrovascular accident
Gale Copyright: Copyright 2010 Gale, Cengage Learning. All rights reserved.